- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05806983
Evaluation of the Efficiency of the Technology-Based Psychosocial Empowerment Program Program
Evaluation of the Efficiency of the Technology-Based Psychosocial Empowerment Program for Home Care of Children With Cancer and Their Parents
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Hazal Ozdemir Koyu, MD
- Phone Number: 905393239630
- Email: hazalozdemirkoyu@gazi.edu.tr
Study Locations
-
-
-
Ankara, Turkey
- Gazi University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- For children's:
Children between the ages of 8-18, Those receiving cancer treatment (leukemias and solid tumors) and completing the first 2 months of the treatment process, Children with tablets, android phones and internet access Children whose parents and themselves agree to participate in the study, Children who can continue the study for 4-6 weeks,
For primary care parents, Parents who can speak Turkish, Parents who can use computers and android mobile phones, Parents who agreed to participate in the study, Parents who can continue the study for 4-6 weeks,
Exclusion Criteria:
- Newly diagnosed children (in induction phase), Children who are in the terminal period or who are treated for relapse, Presence of another important disease (such as chronic disease, psychiatric diagnosis) in the family that may prevent coping, other than the child followed up with the diagnosis of cancer
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Experimental group
-The experimental group that applied the technology-based psychosocial program
|
A technology-based model-based psychosocial empowerment program will be implemented for parents and children in the control group.
|
|
No Intervention: Control group
Control group receiving standard care
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Coping and Adaptation Process Scale
Time Frame: Change from Baseline level 'Coping and Adaptation Process Scale' to 2 months (change is being assessed)
|
The scale is a scale that enables individuals to define coping and adaptation strategies in critical and difficult situations.
The scale consists of 47 items and five sub-dimensions.
Scale items are scored between 1 and 4. As the score obtained from the scale and subscales increases, it is interpreted as the use of effective coping methods increases.
|
Change from Baseline level 'Coping and Adaptation Process Scale' to 2 months (change is being assessed)
|
|
General Self-Efficacy Scale-Pediatric Cancer Version
Time Frame: Change from Baseline level 'Self Efficacy' to 2 months (change is being assessed)
|
It is a one-dimensional, 10-item scale used to evaluate self-efficacy in children aged 8-18 years with cancer.As the score obtained from the scale increases, the level of self-efficacy also increases.
|
Change from Baseline level 'Self Efficacy' to 2 months (change is being assessed)
|
|
Pediatric Cancer Coping Scale
Time Frame: Change from Baseline level 'Pediatric Cancer Coping Scale' to 2 months (change is being assessed)
|
It was developed to evaluate coping in children aged 7-18 years with cancer diagnosis.
The scale consists of 3 sub-dimensions as cognitive coping, problem-focused coping and defensive coping.
The higher the score, the higher the coping strategies.
|
Change from Baseline level 'Pediatric Cancer Coping Scale' to 2 months (change is being assessed)
|
|
General Self-Efficacy Scale
Time Frame: Change from Baseline level 'Self Efficacy' to 2 months (change is being assessed)
|
It is a one-dimensional scale developed to evaluate the general self-efficacy level of adults.As the score obtained from the scale increases, the level of self-efficacy also increases.
|
Change from Baseline level 'Self Efficacy' to 2 months (change is being assessed)
|
|
Problem Solving Inventory
Time Frame: Change from Baseline level 'Problem Solving Inventory' to 2 months (change is being assessed)
|
It is a scale that measures the problem solving skills of individuals according to the perception of the individual.The inventory consists of three sub-dimensions: Safe in Problem Solving, Approach Avoidance Style and Personal Control.Low scores from the inventory indicate the ability to produce effective solutions to problems, while high scores indicate the inability to find effective solutions to problems.
|
Change from Baseline level 'Problem Solving Inventory' to 2 months (change is being assessed)
|
|
State-Trait Anxiety Inventory for Children
Time Frame: Change from Baseline level 'State-Trait Anxiety' to 2 months (change is being assessed)
|
The 'State Anxiety Scale' for children between the ages of 8-18 was created to determine what the child feels at that moment, and the 'Trait Anxiety Scale' was created to determine what they usually feel.
The higher the score, the higher the anxiety level.
|
Change from Baseline level 'State-Trait Anxiety' to 2 months (change is being assessed)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
SSPedi: Symptom Screening Scale in Pediatric Patients
Time Frame: While the intervention continues (1 months), the log records of the scale on the website will be evaluated.
|
The screening tool includes 15 symptoms that evaluate the symptoms children have experienced in the last two days.
Each symptom is evaluated with a 5-point Likert-type scoring system, and the score range varies between 0-60.
Higher scores indicate that the number of symptoms and the discomfort they cause increase.
|
While the intervention continues (1 months), the log records of the scale on the website will be evaluated.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Hazal Ozdemir Koyu, MD, Gazi University
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- Technology Based Program
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.